Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
1.650
-0.010 (-0.60%)
At close: Oct 13, 2025, 4:00 PM EDT
1.610
-0.040 (-2.42%)
Pre-market: Oct 14, 2025, 9:13 AM EDT
Autolus Therapeutics Revenue
Autolus Therapeutics had revenue of $20.92M in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $29.93M, up 185.17% year-over-year. In the year 2024, Autolus Therapeutics had annual revenue of $10.12M with 496.00% growth.
Revenue (ttm)
$29.93M
Revenue Growth
+185.17%
P/S Ratio
14.37
Revenue / Employee
$46,052
Employees
650
Market Cap
439.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.12M | 8.42M | 496.00% |
| Dec 31, 2023 | 1.70M | -4.66M | -73.30% |
| Dec 31, 2022 | 6.36M | 4.03M | 172.96% |
| Dec 31, 2021 | 2.33M | 615.00K | 35.86% |
| Dec 31, 2020 | 1.72M | -1.19M | -41.02% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AUTL News
- 4 weeks ago - Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025 - GlobeNewsWire
- 2 months ago - Autolus Therapeutics: Expanding The Reach Of Its CD19 Therapy, But Still Far From Profitable - Seeking Alpha
- 2 months ago - Autolus Therapeutics plc (AUTL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 2 months ago - Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025 - GlobeNewsWire
- 3 months ago - Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) - GlobeNewsWire
- 3 months ago - Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress - GlobeNewsWire